BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

>2 years Efficacy phase (II)Post-Trial Drug Access No Placebo Partially Remote Standard Medicines Oral InjectionNeurologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Braftovi

Braftovi is a cancer medicine used to treat certain advanced melanomas and some colorectal cancers that have a specific genetic mutation.

Libtayo

Libtayo is a cancer medicine that helps the immune system find and fight certain advanced skin and lung cancers.

Mektovi

Mektovi is a medicine used to treat advanced melanoma, a type of skin cancer, in patients whose tumors have specific genetic changes.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Binimetinib

Binimetinib is a targeted cancer treatment that blocks a protein pathway to slow growth of certain tumors, including some melanomas.

Cemiplimab

Cemiplimab is a substance that helps the immune system find and attack certain cancers by blocking a protein that suppresses immune cells.

Encorafenib

Encorafenib is a substance that targets cancer cells with a specific BRAF gene mutation to help slow tumor growth.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Cotellic

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Complexo Hospitalario Universitario A Coruna

Oncology

A Coruña, Spain

Hospital Universitari Dexeus Grupo Quironsalud

Oncology

Amorebieta, Spain

Hospital Universitari Vall D Hebron

Oncology

Barcelona, Spain

Sponsor: Grupo Espanol Multidisciplinar De Melanoma

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.